BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11510923)

  • 1. Antineuronal nuclei immunohistochemical staining patterns in childhood ependymomas.
    Parker JR; Armstrong DL; Strother D; Rudman DM; Dauser RC; Laurent JP; Deyd J; Rouah PE
    J Child Neurol; 2001 Aug; 16(8):548-52. PubMed ID: 11510923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers of primitive neuroectodermal tumors and other pediatric central nervous system tumors. Monoclonal antibodies to neuronal and glial antigens distinguish subsets of primitive neuroectodermal tumors.
    Molenaar WM; Jansson DS; Gould VE; Rorke LB; Franke WW; Lee VM; Packer RJ; Trojanowski JQ
    Lab Invest; 1989 Dec; 61(6):635-43. PubMed ID: 2557487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas.
    Hasselblatt M; Paulus W
    Acta Neuropathol; 2003 Oct; 106(4):385-8. PubMed ID: 12898159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-1 receptor type I, IL-1 receptor antagonist, and TGF-beta 1 mRNAs in pediatric astrocytomas, ependymomas, and primitive neuroectodermal tumors.
    Ilyin SE; González-Gómez I; Gilles FH; Plata-Salamán CR
    Mol Chem Neuropathol; 1998 Feb; 33(2):125-37. PubMed ID: 9565970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
    Preusser M; Budka H; Rössler K; Hainfellner JA
    Histopathology; 2007 Feb; 50(3):365-70. PubMed ID: 17257132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis.
    de Bont JM; den Boer ML; Kros JM; Passier MM; Reddingius RE; Smitt PA; Luider TM; Pieters R
    J Neuropathol Exp Neurol; 2007 Jun; 66(6):505-16. PubMed ID: 17549010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunophenotype of ependymomas.
    Vege KD; Giannini C; Scheithauer BW
    Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):25-31. PubMed ID: 10937045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supratentorial primitive neuroectodermal tumours of the brain: multidirectional differentiation does not influence prognosis. A clinicopathological report of 18 patients.
    Visée S; Soltner C; Rialland X; Machet MC; Loussouarn D; Milinkevitch S; Pasco-Papon A; Mercier P; Rousselet MC
    Histopathology; 2005 Apr; 46(4):403-12. PubMed ID: 15810952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic ependymoma with ependymoblastic multilayered rosettes.
    Nobusawa S; Suzuki A; Nagaishi M; Isoda K; Ikota H; Yokoo H; Hirato J; Nakazato Y
    Hum Pathol; 2013 Nov; 44(11):2597-602. PubMed ID: 23791209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primitive neuroectodermal tumor of central nervous system with features of ependymoblastoma and neuroblastoma: a clinicopathologic study of 4 cases].
    Wang R; Guan W; Wu X; Zhang W; Jiang B; Ma J; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):403-7. PubMed ID: 25208992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic use of D2-40 and annexin-1 in ependymal tumors].
    Wang YF; Piao YS; Lu DH; Chen L; Wang W; Yang H; Wei LF
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):595-8. PubMed ID: 22177242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.
    Haberler C; Laggner U; Slavc I; Czech T; Ambros IM; Ambros PF; Budka H; Hainfellner JA
    Am J Surg Pathol; 2006 Nov; 30(11):1462-8. PubMed ID: 17063089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cyclo-oxygenase-2 in ependymal tumors.
    Roma AA; Prayson RA
    Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study of ependymal neoplasms: histological subtypes and glial and epithelial characteristics.
    Kaneko Y; Takeshita I; Matsushima T; Iwaki T; Tashima T; Fukui M
    Virchows Arch A Pathol Anat Histopathol; 1990; 417(2):97-103. PubMed ID: 1695040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of nestin in pediatric brain tumors.
    Almqvist PM; Mah R; Lendahl U; Jacobsson B; Hendson G
    J Histochem Cytochem; 2002 Feb; 50(2):147-58. PubMed ID: 11799134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas.
    Fung KM; Rorke LB; Giasson B; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2003 Aug; 106(2):167-75. PubMed ID: 12783249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD99 immunoreactivity in ependymoma.
    Choi YL; Chi JG; Suh YL
    Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):125-9. PubMed ID: 11396629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of reactivity with anti-glycolipid antibodies in human primary brain tumors.
    Li J; Pearl DK; Pfeiffer SE; Yates AJ
    J Neurosci Res; 1994 Oct; 39(2):148-58. PubMed ID: 7530777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.